POLARIS PHARMACEUTICALS INC has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2000. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are TSUMURA & CO, FIBROSTATIN S L and WANBANGDE PHARMACEUTICAL GROUP CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | Taiwan | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement | |
#4 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations | |
#4 | Peptides | |
#5 | Analysing materials | |
#6 | Combinatorial chemistry | |
#7 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Webber Stephen E | 7 |
#2 | Jenson James C | 5 |
#3 | Sworin Michael | 5 |
#4 | Tao Xueliang | 4 |
#5 | Brin Elena | 4 |
#6 | Almassy Robert J | 3 |
Publication | Filing date | Title |
---|---|---|
WO2018045142A1 | Immune checkpoint inhibitors, compositions and methods thereof | |
CA3028727A1 | Ck2 inhibitors, compositions and methods thereof | |
AU2005201264A1 | Inhibitors of binding between proteins and macromolecular ligands | |
AU6937100A | Inhibitors of binding between proteins and macromolecular ligands |